Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non-small cell lung cancer.
Biomarker
circulating genetically abnormal cells
early detection
non-small-cell lung cancer
small nodules
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
23
07
2020
revised:
21
08
2020
accepted:
23
08
2020
pubmed:
30
9
2020
medline:
7
8
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
Circulating genetically abnormal cells (CACs) with specific chromosome variations have been confirmed to be present in non-small cell lung cancer (NSCLC). However, the diagnostic performance of CAC detection remains unclear. This study aimed to evaluate the potential clinical application of the CAC test for the early diagnosis of NSCLC. In this prospective study, a total of 339 participants (261 lung cancer patients and 78 healthy volunteers) were enrolled. An antigen-independent fluorescence in situ hybridization was used to enumerate the number of CACs in peripheral blood. Patients with early-stage NSCLC were found to have a significantly higher number of CACs than those of healthy participants (1.34 vs. 0.19; P < 0.001). The CAC test displayed an area under the receiver operating characteristic (ROC) curve of 0.76139 for discriminating stage I NSCLC from healthy participants with 67.2% sensitivity and 80.8% specificity, respectively. Compared with serum tumor markers, the sensitivity of CAC assays for distinguishing early-stage NSCLC was higher (67.2% vs. 48.7%, P < 0.001), especially in NSCLC patients with small nodules (65.4% vs. 36.5%, P = 0.003) and ground-glass nodules (pure GGNs: 66.7% vs. 40.9%, P = 0.003; mixed GGNs: 73.0% vs. 43.2%, P < 0.001). CAC detection in early stage NSCLC was feasible. Our study showed that CACs could be used as a promising noninvasive biomarker for the early diagnosis of NSCLC. What this study adds: This study aimed to evaluate the potential clinical application of the CAC test for the early diagnosis of NSCLC. Significant findings of the study: CAC detection in early stage NSCLC was feasible. Our study showed that CACs could be used as a promising noninvasive biomarker for the early diagnosis of NSCLC.
Sections du résumé
BACKGROUND
Circulating genetically abnormal cells (CACs) with specific chromosome variations have been confirmed to be present in non-small cell lung cancer (NSCLC). However, the diagnostic performance of CAC detection remains unclear. This study aimed to evaluate the potential clinical application of the CAC test for the early diagnosis of NSCLC.
METHODS
In this prospective study, a total of 339 participants (261 lung cancer patients and 78 healthy volunteers) were enrolled. An antigen-independent fluorescence in situ hybridization was used to enumerate the number of CACs in peripheral blood.
RESULTS
Patients with early-stage NSCLC were found to have a significantly higher number of CACs than those of healthy participants (1.34 vs. 0.19; P < 0.001). The CAC test displayed an area under the receiver operating characteristic (ROC) curve of 0.76139 for discriminating stage I NSCLC from healthy participants with 67.2% sensitivity and 80.8% specificity, respectively. Compared with serum tumor markers, the sensitivity of CAC assays for distinguishing early-stage NSCLC was higher (67.2% vs. 48.7%, P < 0.001), especially in NSCLC patients with small nodules (65.4% vs. 36.5%, P = 0.003) and ground-glass nodules (pure GGNs: 66.7% vs. 40.9%, P = 0.003; mixed GGNs: 73.0% vs. 43.2%, P < 0.001).
CONCLUSIONS
CAC detection in early stage NSCLC was feasible. Our study showed that CACs could be used as a promising noninvasive biomarker for the early diagnosis of NSCLC.
KEY POINTS
What this study adds: This study aimed to evaluate the potential clinical application of the CAC test for the early diagnosis of NSCLC. Significant findings of the study: CAC detection in early stage NSCLC was feasible. Our study showed that CACs could be used as a promising noninvasive biomarker for the early diagnosis of NSCLC.
Identifiants
pubmed: 32989915
doi: 10.1111/1759-7714.13654
pmc: PMC7606026
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3234-3242Subventions
Organisme : National Natural Science Foundation of China
ID : 81672304
Pays : International
Organisme : National Natural Science Foundation of China
ID : 81772488
Pays : International
Organisme : National Natural Science Foundation of China
ID : 81772484
Pays : International
Organisme : Program for Guangdong Introducing Innovative and Entrepreneurial Teams
ID : 2019ZT08Y297
Pays : International
Organisme : Tianjin Cancer Hospital Clinical Trial Project
ID : C1705
Pays : International
Organisme : National Key Research and Development Program of China
ID : 2016YFC0905500
Pays : International
Organisme : National Key Research and Development Program of China
ID : 2016YFC0905501
Pays : International
Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Lung Cancer. 2017 May;107:100-107
pubmed: 27180141
Chest. 2011 Dec;140(6):1669-1670
pubmed: 22147832
Cancer Lett. 2012 Jun 1;319(1):49-55
pubmed: 22202642
Am J Respir Crit Care Med. 2016 Mar 1;193(5):542-51
pubmed: 26485620
Ann Intern Med. 2013 Sep 17;159(6):411-420
pubmed: 23897166
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
J Thorac Dis. 2018 Apr;10(Suppl 7):S876-S881
pubmed: 29780634
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Chest. 2004 Sep;126(3):744-7
pubmed: 15364751
Transl Lung Cancer Res. 2017 Aug;6(4):431-443
pubmed: 28904887
Science. 2013 Sep 13;341(6151):1186-8
pubmed: 24031008
Sci Rep. 2016 Aug 24;6:31985
pubmed: 27555497
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Nat Rev Clin Oncol. 2018 Feb;15(2):71-72
pubmed: 29158589
Thorax. 2015 May;70(5):476-81
pubmed: 25628310
J Clin Oncol. 2011 Dec 20;29(36):4781-8
pubmed: 22105822
Clin Cancer Res. 2009 Nov 15;15(22):6980-6
pubmed: 19887487
Nat Rev Clin Oncol. 2015 Mar;12(3):135-46
pubmed: 25533947
Nat Rev Cancer. 2016 Aug;16(8):525-37
pubmed: 27388699
Cells. 2019 Nov 08;8(11):
pubmed: 31717458
Cancers (Basel). 2010 Mar 22;2(1):190-208
pubmed: 24281040
J Thorac Imaging. 2017 Jan;32(1):63-67
pubmed: 27753752
Am J Respir Crit Care Med. 2016 Jan 15;193(2):116-30
pubmed: 26583808
Ann Transl Med. 2018 Mar;6(5):95
pubmed: 29666818
Ann Oncol. 2015 Jul;26(7):1408-15
pubmed: 25846554
Clin Cancer Res. 2010 Aug 1;16(15):3976-87
pubmed: 20651054
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Diagn Interv Radiol. 2018 Jul;24(4):209-212
pubmed: 30091711
Am J Respir Crit Care Med. 2006 Sep 15;174(6):684-8
pubmed: 16799079